InnoPharmax Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

InnoPharmax's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been declining at an average rate of 21.2% per year.

Anahtar bilgiler

-3.6%

Kazanç büyüme oranı

2.6%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi18.5%
Gelir büyüme oranı-21.2%
Özkaynak getirisi-19.3%
Net Marj-241.5%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Would Shareholders Who Purchased InnoPharmax's (GTSM:4172) Stock Five Years Be Happy With The Share price Today?

Feb 22
Would Shareholders Who Purchased InnoPharmax's (GTSM:4172) Stock Five Years Be Happy With The Share price Today?

We Think InnoPharmax (GTSM:4172) Can Afford To Drive Business Growth

Dec 04
We Think InnoPharmax (GTSM:4172) Can Afford To Drive Business Growth

Gelir ve Gider Dağılımı

InnoPharmax nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

TPEX:4172 Gelir, gider ve kazançlar (TWD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 2435-842971
31 Mar 2440-772665
31 Dec 2346-712359
30 Sep 2348-772360
30 Jun 2349-842361
31 Mar 2339-942266
31 Dec 2229-1032172
30 Sep 2232-1022270
30 Jun 2234-1012368
31 Mar 2241-972264
31 Dec 2148-932260
30 Sep 2179-772260
30 Jun 21110-622360
31 Mar 21123-532461
31 Dec 20137-442662
30 Sep 20128-542666
30 Jun 20119-632670
31 Mar 20102-762478
31 Dec 1985-882386
30 Sep 1966-882387
30 Jun 1946-882387
31 Mar 1951-872684
31 Dec 1856-862880
30 Sep 1849-1053385
30 Jun 1839-1243791
31 Mar 1841-14341109
31 Dec 1744-16245127
30 Sep 1758-4444128
30 Jun 1759-6551148
31 Mar 1752-5754136
31 Dec 1646-4956124
30 Sep 1637-16056126
30 Jun 1645-13449108
31 Mar 1645-13047107
31 Dec 1544-12646106
30 Sep 1545-12348103
30 Jun 1546-12151100
31 Mar 1578-8951103
31 Dec 14109-5851105
30 Sep 14104-6549112
30 Jun 14100-7246119
31 Mar 1467-10645120
31 Dec 1334-14143122

Kaliteli Kazançlar: 4172 is currently unprofitable.

Büyüyen Kar Marjı: 4172 is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4172 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Büyüme Hızlandırma: Unable to compare 4172's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: 4172 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).


Özkaynak Getirisi

Yüksek ROE: 4172 has a negative Return on Equity (-19.26%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin